# Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

> **NCT03711864** · PHASE1 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** IM21 CAR-T cells

## Key facts

- **NCT ID:** NCT03711864
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-25
- **Primary completion:** 2021-10-10
- **Final completion:** 2021-12-20
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2020-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711864, "Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03711864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*